HSDT Solana Company
USHealthcareAs of 2026-07-10 16:00
Why HSDT matters now
Solana Company (HSDT) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.75 with -4.37% on the session and $102.2M in market capitalization; recent performance reads 1-month -25.00% and YTD -43.94%.
The latest financial table shown here is Q1 2026, with revenue of $3.6M, net income of $-99.8M, and EPS of $-1.30. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -18.8%.
The latest indexable market news headline is "Solana Company Partners with Alatau City to Advance Digital Asset Infrastructure and Blockchain Adoption in Central Asia" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Jiang Cosmo Yi filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.63
P/S
9.86
EV/EBITDA
-0.67
DCF Value
$-11.67
FCF Yield
-18.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.2%
Operating Margin
-196.6%
Net Margin
-1427.1%
ROE
-155.3%
ROA
-68.2%
ROIC
-9.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.6M | $-99.8M | $-1.30 |
| Q4 2025 | $5.2M | $325.6M | $4.25 |
| FY 2025 | $6.0M | $-40.9M | $-1.85 |
| Q3 2025 | $697.0K | $-352.8M | $-32.89 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.03
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.